$EVAX

$2.85▲ -3.1% YTD

8 SEC 13D/G filings tracked · Last updated Nov 9, 2026

Filing History

News

EVAX ▼ -3.1% - Evaxion A/S

CP $2.85▲ -3.1%Nov 9, 2026 · ThinkSabio Blog

$EVAX - Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement…

News

EVAX ▲ +2.9% - Evaxion A/S

CP $2.86▲ +2.9%Nov 6, 2026 · ThinkSabio Blog

$EVAX - New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01…

News

EVAX ▼ -2.3% - Evaxion A/S

CP $2.94▲ -2.3%Nov 4, 2026 · ThinkSabio Blog

$EVAX - Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meetin…

News

EVAX ▼ -1.4% - Evaxion A/S

CP $2.86▲ -1.4%Nov 3, 2026 · ThinkSabio Blog

$EVAX - Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting…

News

EVAX ▼ -2.2% - Evaxion A/S

CP $3.63▲ -2.2%Oct 23, 2026 · ThinkSabio Blog

$EVAX - Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with perso…

News

EVAX ▲ +15.7% - Evaxion A/S

CP $3.25▲ +15.7%Oct 19, 2026 · ThinkSabio Blog

$EVAX - Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01…

News

EVAX ▲ +4.1% - Evaxion A/S

CP $3.28▲ +4.1%Oct 2, 2026 · ThinkSabio Blog

$EVAX - Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting…

News

EVAX ▲ +1.9% - Evaxion A/S

CP $3.19▲ +1.9%Sep 14, 2026 · ThinkSabio Blog

$EVAX - Evaxion applies its AI-Immunology™ platform in autoimmune diseases…